Orthocell (ASX:OCC) Debt-to-Asset : 0.02 (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Orthocell Debt-to-Asset?

Orthocell's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was A$0.17 Mil. Orthocell's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was A$0.49 Mil. Orthocell's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was A$40.04 Mil. Orthocell's debt to asset for the quarter that ended in Dec. 2024 was 0.02.

Orthocell Debt-to-Asset Historical Data

The historical data trend for Orthocell's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orthocell Debt-to-Asset Chart

Orthocell Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.03

0.01

0.02

0.03

Orthocell Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.02	0.02	0.03	0.03	0.02

Competitive Comparison of Orthocell's Debt-to-Asset

For the Biotechnology subindustry, Orthocell's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orthocell's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orthocell's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Orthocell's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Orthocell Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Orthocell's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.149	+	0.541)	/	26.615
	=	0.03

Orthocell's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.165	+	0.493)	/	40.04
	=	0.02

Orthocell (ASX:OCC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Orthocell Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Orthocell's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Orthocell Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orthocell Ltd (ASX:OCC) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

90 South Street, Building 191, Murdoch University, Murdoch, Perth, WA, AUS, 6150

Website

https://www.orthocell.com.au

Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir which is a collagen wrap used in peripheral nerve repair; and OrthoACI an implantation used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline such as Tendon Cell Therapy and Collagen Medical Device Platform.